Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

Today's health news includes what RFK Jr. can do on vaccines, escaped monkeys, and who know in the Make America Healthy Again ...

The modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is approved in several countries for the prevention of mpox and smallpox in adults, but insufficient data are available to support ...

The World Health Organization (WHO) has declared a global health emergency over a new strain of mpox that is spreading ...

About The Study: The modified vaccinia Ankara–Bavarian Nordic (MVA-BN) vaccination generated mpox antibodies that waned by 6 to 12 months. In participants who received 2 doses of MVA-BN vaccine ...

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

An initial 899,000 vaccine doses have been allocated to Nigeria and 8 other countries across Africa that have been hit ...

The announcement came on the heels of the arrival of the first MVA-BN vaccines to the Democratic Republic of Congo (DRC), the epicentre of the epidemic. "This first prequalification of a vaccine ...

Regardless of 1 or 2 doses, mpox antibodies wane by 6 to 12 months. HealthDay News — Immunity against mpox may be waning for those vaccinated with the modified vaccinia Ankara-Bavarian Nordic ...

COPENHAGEN, Denmark, September 26, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced an agreement with UNICEF for the supply of 1 million doses of the MVA-BN® mpox vaccine for countries in ...

Bavarian Nordic is looking to expand the approval label of its MVA-BN mpox/smallpox vaccine to include children two to 11 years of age and has started a Phase II trial to support the approval.

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age. COPENHAGEN, Denmark, October 29, 2024 – Bavarian ...